Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
VEGF
Fierce Pharma
Editor's Corner—Summit must submit to Big Pharma, stat
The debatable HARMONi data, along with the trial design flaws and a rapidly evolving competitive landscape, suggest a need for Summit to partner up.
Angus Liu
Sep 10, 2025 2:50pm
BioNTech, BMS tout first global data for PD-L1xVEGF drug in SCLC
Sep 8, 2025 11:00am
RemeGen sells Asia rights to VEGF/FGF eye drug in $180M deal
Aug 19, 2025 7:18am
Minghui raises $131M to fund JAK inhibitor launch, ADC trials
Aug 7, 2025 8:15am
Instil's licensed PD-L1xVEGF bispecific shows promise in China
Jul 31, 2025 2:10pm
BMS inks $11B biobucks BioNTech deal to join bispecific rush
Jun 2, 2025 8:59am
